# Evaluating the Bioequivalence of HIP1403 and HGP0919 Suspensions

> **NCT02941731** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HIP1403
- **DRUG:** HGP0919

## Key facts

- **NCT ID:** NCT02941731
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2016-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02941731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02941731, "Evaluating the Bioequivalence of HIP1403 and HGP0919 Suspensions". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02941731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*